WhatPeptide

OS-01

A topical senomorphic peptide developed by OneSkin Inc. (San Francisco). Reduces senescent cell burden by up to 50% (SA-β-gal+ cells) and reversed epigenetic age by 2.6 years in 79-year-old ex vivo skin via the proprietary MolClock assay (Zonari et al., npj Aging 2023). INCI name: Decapeptide-52. Not a senolytic — it modulates senescent cell behavior rather than killing them.

Preliminary evidence Unregulated Senomorphic

Written by WhatPeptide Editorial Team · Last updated 2026-03-18

Half-life

Not characterized (topical application; no systemic PK data)

Dosage range

Topical application as directed per OneSkin formulations (OS-01 FACE, OS-01 BODY). Clinical trials: twice-daily application for 12 weeks

Administration

Topical

Research level

Preliminary

How OS-01 works

Stabilizes PP2A phosphatase activity and modulates CDK2AP1 (CDK2 Associated Protein 1) expression, leading to CDK2 activation. Reduces SASP markers (IL-6, IL-8, MMP-1) and senescence markers (p16, p21) without inducing apoptosis of senescent cells, distinguishing it from senolytics.

Also known as: Pep 14, Decapeptide-52, OneSkin OS-01

Research relevance

Hair & Skin
Moderate relevance 75
Anti-Aging & Longevity
Moderate relevance 70

Side effects & safety

Skin irritation (rare) Limited long-term safety data No systemic effects expected from topical application

Contraindications

Known sensitivity to peptide-based skincare ingredients
Open wounds or compromised skin barrier at application site

Consult a healthcare provider before use if any of these apply to you.

FAQ

What is OS-01? +
A topical senomorphic peptide developed by OneSkin Inc. (San Francisco). Reduces senescent cell burden by up to 50% (SA-β-gal+ cells) and reversed epigenetic age by 2.6 years in 79-year-old ex vivo skin via the proprietary MolClock assay (Zonari et al., npj Aging 2023). INCI name: Decapeptide-52. Not a senolytic — it modulates senescent cell behavior rather than killing them. Its mechanism of action is based on preliminary or early-stage research.
What is OS-01 researched for? +
OS-01 has the strongest research relevance for Hair & Skin, Anti-Aging & Longevity. Evidence is based on preliminary or early-stage research.
What are the side effects of OS-01? +
Reported side effects include Skin irritation (rare), Limited long-term safety data, No systemic effects expected from topical application. Key contraindications: Known sensitivity to peptide-based skincare ingredients; Open wounds or compromised skin barrier at application site.
Is OS-01 FDA approved? +
OS-01 is not FDA-approved. It is available as a research compound or through compounding pharmacies in some jurisdictions.
How is OS-01 administered? +
OS-01 is typically administered via topical route. Researched dosage range: Topical application as directed per OneSkin formulations (OS-01 FACE, OS-01 BODY). Clinical trials: twice-daily application for 12 weeks. Half-life: Not characterized (topical application; no systemic PK data).

Explore similar peptides

GHK-Cu

Moderate evidence

Cosmetic

A naturally occurring copper-binding tripeptide widely studied in skin and hair biology and extracellular matrix remodeling. Note: FDA Category 2 applies to injectable routes only. Non-injectable administration (topical, nasal, oral) remains Category 1 (permitted for compounding).

AHK-Cu

Preliminary evidence

Cosmetic

AHK-Cu is a copper-binding tripeptide studied for its ability to stimulate hair follicle proliferation and promote wound healing through copper-dependent enzymatic pathways. It is a less widely studied relative of GHK-Cu but shares overlapping mechanisms relevant to hair and skin biology.

GHK

Moderate evidence

Cosmetic

GHK is the parent tripeptide that forms the copper-chelating complex GHK-Cu, studied for its own biological activities including gene expression modulation, tissue remodeling, and anti-inflammatory effects. It naturally declines with age and is found in plasma, saliva, and urine.

CJC-1295

Moderate evidence

GH Secretagogue

A modified GHRH analog designed to prolong endogenous GH pulse support through albumin binding (DAC form). Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.